The PCSK9 inhibitor blocks the PCSK9 enzyme, resulting in more LDL receptors available to remove LDL from the blood, which produces in a decrease in LDL blood levels. For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).

2021年9月1日 · PCSK9 inhibitors are an injectable treatment for high LDL cholesterol that may provide a safe alternative for people who can’t take statins or who have genetic conditions that increase the...

2022年2月17日 · PCSK9 inhibitors are a type of cholesterol-lowering drug. They reduce your low-density lipoprotein (LDL) cholesterol or “bad” cholesterol. This medication may be especially helpful if you’ve had high cholesterol throughout your life.

Elevated levels of circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with increased low-density lipoprotein (LDL) and worse cardiovascular outcomes. Antibodies to PCSK9 have been approved by regulatory agencies for the treatment of individuals with inadequately treated levels of LDL-cholesterol (LDL-C).

2024年2月25日 · Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as an important regulator of cholesterol metabolism. In the United States, 2 fully humanized monoclonal antibodies—alirocumab and evolocumab— have been approved by the US Food and Drug Administration (FDA) to inhibit or reduce PCSK9 activity.

2024年9月30日 · PCSK9 inhibitors are used to treat high cholesterol and familial hypercholesterolemia. They can also help reduce the risk of heart attack and stroke in people with heart disease. These medications work by blocking a protein in the body called PCSK9, which then helps your liver remove more LDL cholesterol (the "bad" cholesterol) from your blood.

2015年11月20日 · PCSK9 inhibitors fill a therapeutic niche for patients with familial hypercholesterolemia or patients with statin intolerance who are not able to achieve the desired LDL-C level with conventional treatments.

PCSK9 inhibitors are a new class of drugs that lower low-density lipoprotein (LDL), or “bad,” cholesterol. PCSK9 inhibitors are set to revolutionize the management of atherosclerotic risk. There are two FDA-approved medications: alirocumab (Praluent) and evolocumab (Repatha).

2022年3月26日 · PCSK9 inhibitors are prescription medications that are injected under the skin (subcutaneously), used to lower low-density lipoprotein cholesterol levels (LDL-C levels) and lower the risk of cardiovascular events.

2024年3月12日 · The PCSK9 inhibitors are used for the treatment of high-risk patients with elevated cholesterol, especially when statins aren't adequate. They work by blocking PCSK9, leaving more receptors available to capture your "bad" cholesterol (LDL) for break down and removal from the blood.